EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company’s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET.

Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; and Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Houston, Deputy Chair For Ophthalmology, Blanton Eye Institute.

To access the event, please dial (877) 870-4263 from the U.S. and Canada or (412) 317-0790 from international locations at least 10 minutes prior to the start time and ask to be joined to the EyePoint call. A live video webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Contacts
Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
eyepoint@argotpartners.com

Media:
Thomas Gibson
201-476-0322
tom@tomgibsoncommunications.com  

Staff

Recent Posts

TE Connectivity declares quarterly dividend

GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…

30 minutes ago

SRM Equity Partners Acquires RF Technologies, a Leader in Safety and Security Solutions for Healthcare and Senior Living

BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…

30 minutes ago

New Findings from NSC Grant Recipients Help Tackle America’s Most Common Workplace Injury

MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…

30 minutes ago

Version 3.0 AI Automation Platform Launches at VGM’s Heartland Conference

Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…

30 minutes ago

AllSci Wins Grant to Expand AI Platform for Pharma and Biotech R&D: Accelerating Hypothesis-Driven Discovery

Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…

30 minutes ago

RIVANNA selected for prestigious MedTech Innovator 2025 Accelerator Cohort

— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…

30 minutes ago